Intensive Glycaemic Control and Cancer Risk in Type 2 Diabetes: a Meta-analysis of Major Trials

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2010 Oct 21

PMID 20959956

Citations 67

Authors

J A Johnson

S L Bowker

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: The purpose of this study was to explore the relationship between hyperglycaemia in type 2 diabetes and risk of cancer incidence or cancer mortality. We were interested to determine if data from major randomised controlled trials would support a hypothesis that improving glycaemic control may reduce the risk of cancer outcomes.

Methods: We included major randomised controlled trials conducted with an overall aim of intensified glycaemic control in type 2 diabetes. We abstracted data from published papers and supplemental material and conducted separate meta-analyses of cancer mortality and cancer incidence.

Results: Four trials reported cancer mortality for the intensive (222 events in 53,892 person-years) and standard control (155 events in 38,743 person-years) arms (UK Prospective Diabetes Study [UKPDS] 33, UKPDS 34, Action to Control Cardiovascular Risk in Diabetes [ACCORD] and Veterans Affairs Diabetes Trial [VADT]); the summary risk ratio for cancer mortality was 1.00 (95% CI 0.81-1.24; I² = 0%). Excluding the UKPDS metformin trial resulted in a pooled risk estimate of 1.03 (95% CI 0.83-1.29; I² = 0%). Three trials reported cancer incidence for the study arms (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation [ADVANCE], PROspective pioglitAzone Clinical Trial In macroVascular Events [PROactive], Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes [RECORD]) with 357 events in 47,974 person-years with improved glycaemic control and 380 events in 45,009 person-years in the control arms; the pooled risk ratio for cancer incidence was 0.91 (95% CI 0.79-1.05; I² = 0%).

Conclusions/interpretation: Data from large randomised controlled trials of intensified glycaemic control suggest that cancer risk is not reduced by improving glycaemic control in type 2 diabetes. These data therefore do not support the hypothesis that hyperglycaemia is causally linked to increased cancer risk.

Citing Articles

Association between severity of diabetic complications and risk of cancer in middle-aged patients with type 2 diabetes.

Tseng Y, Tsan Y, Chen P J Diabetes Investig. 2024; 16(1):16-24.

PMID: 39575899 PMC: 11693530. DOI: 10.1111/jdi.14364.

Exocrine Pancreas in Type 1 and Type 2 Diabetes: Different Patterns of Fibrosis, Metaplasia, Angiopathy, and Adiposity.

Wright J, Eskaros A, Windon A, Bottino R, Jenkins R, Bradley A Diabetes. 2023; 73(7):1140-1152.

PMID: 37881846 PMC: 11189834. DOI: 10.2337/db23-0009.

The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities.

Ennis C, Llevenes P, Qiu Y, Dries R, Denis G Front Endocrinol (Lausanne). 2022; 13:1044670.

PMID: 36531496 PMC: 9751481. DOI: 10.3389/fendo.2022.1044670.

The insulin sensitivity Mcauley index (MCAi) is associated with 40-year cancer mortality in a cohort of men and women free of diabetes at baseline.

Moshkovits Y, Rott D, Chetrit A, Dankner R PLoS One. 2022; 17(8):e0272437.

PMID: 35921366 PMC: 9348742. DOI: 10.1371/journal.pone.0272437.

The burden and risks of emerging complications of diabetes mellitus.

Tomic D, Shaw J, Magliano D Nat Rev Endocrinol. 2022; 18(9):525-539.

PMID: 35668219 PMC: 9169030. DOI: 10.1038/s41574-022-00690-7.

References

Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E . Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007; 23(6):479-84. DOI: 10.1002/dmrr.736. View

Gerstein H . Does insulin therapy promote, reduce, or have a neutral effect on cancers?. JAMA. 2010; 303(5):446-7. DOI: 10.1001/jama.2010.60. View

Colhoun H . Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52(9):1755-65. PMC: 2723678. DOI: 10.1007/s00125-009-1453-1. View

Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M . Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92(11):2076-83. PMC: 2361795. DOI: 10.1038/sj.bjc.6602619. View

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254-8. DOI: 10.2337/diacare.29.02.06.dc05-1558. View

Jee S, Ohrr H, Sull J, Yun J, Ji M, Samet J . Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293(2):194-202. DOI: 10.1001/jama.293.2.194. View

Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-12. DOI: 10.1158/0008-5472.CAN-07-2310. View

Pocock S, Smeeth L . Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009; 374(9689):511-3. DOI: 10.1016/S0140-6736(09)61307-6. View

10.

Turnbull F, Abraira C, Anderson R, Byington R, Chalmers J, Duckworth W . Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52(11):2288-98. DOI: 10.1007/s00125-009-1470-0. View

11.

Monami M, Lamanna C, Pala L, Bardini G, Cresci B, Francesconi P . Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes. 2008; 116(3):184-9. DOI: 10.1055/s-2007-992157. View

12.

Larsson S, Orsini N, Wolk A . Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(22):1679-87. DOI: 10.1093/jnci/dji375. View

13.

Chung Y, Han D, Park K, Eun C, Yoo K, Park C . Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum. 2008; 51(5):593-7. DOI: 10.1007/s10350-007-9184-1. View

14.

DAgostino Jr R, DAgostino Sr R . Estimating treatment effects using observational data. JAMA. 2007; 297(3):314-6. DOI: 10.1001/jama.297.3.314. View

15.

Larsson S, Mantzoros C, Wolk A . Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007; 121(4):856-62. DOI: 10.1002/ijc.22717. View

16.

Jonasson J, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G . Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009; 52(9):1745-54. DOI: 10.1007/s00125-009-1444-2. View

17.

Tachibana K, Yamasaki D, Ishimoto K, Doi T . The Role of PPARs in Cancer. PPAR Res. 2008; 2008:102737. PMC: 2435221. DOI: 10.1155/2008/102737. View

18.

Koro C, Barrett S, Qizilbash N . Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf. 2006; 16(5):485-92. DOI: 10.1002/pds.1352. View

19.

Burton J, Goldenberg D, Blumenthal R . Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008; 2008:494161. PMC: 2528255. DOI: 10.1155/2008/494161. View

20.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View